Skip to main content
ABL Diagnostics logo

ABL Diagnostics — Investor Relations & Filings

Ticker · ABLD ISIN · FR0000063034 LEI · 9695002UO0UHM0VKRH38 PA Manufacturing
Open in API
Filings indexed 110 across all filing types
Latest filing 2026-05-11 Earnings Release
Country FR France
Listing PA ABLD

About ABL Diagnostics

https://www.ablsa.com

ABL Diagnostics is a molecular diagnostics company that develops and commercializes solutions for the diagnosis and management of infectious diseases. The company's offerings include in-vitro diagnostic (IVD) medical devices, PCR-based assays such as the UltraGene product line, and integrated software for data analysis and laboratory automation. ABL Diagnostics also provides the Nadis® electronic medical record (EMR) system for clinical data management. The company specializes in genotyping and sequencing technologies, with a primary focus on monitoring drug resistance in viral infections like HIV and viral hepatitis.

Recent filings

Filing Released Lang Actions
Inside Information / News release on accounts, results
Earnings Release Classification · 87% confidence The document is a press release announcing ABL Diagnostics’ annual financial results for the fiscal year ended December 31, 2025. It provides key financial highlights (revenue, operating income, net income, cash flow), growth metrics, and business commentary. It is not the full annual report (10-K) or an attached detailed report; rather it is an initial earnings announcement summarizing performance. Therefore, it fits the Earnings Release category. FY 2025
2026-05-11 English
Informations privilégiées / Communiqué sur comptes, résultats
Earnings Release Classification · 88% confidence The document is a press release announcing ABL Diagnostics’ annual financial results for the year ended December 31, 2025, with headline metrics (revenue, operational profit, net result) and highlights of growth, international expansion, and key partnerships. It does not include full audited financial statements or detailed report analysis typical of a 10-K/Annual Report. This style and content correspond to an Earnings Release. FY 2025
2026-05-11 French
Annual financial and audit reports / Terms of availability of the annual financial report
Report Publication Announcement Classification · 92% confidence The document is a press release stating that the company’s 2025 Annual Financial Report has been filed with the AMF and is available on the website, without containing the report’s contents itself. It invites stakeholders to consult the report via a link. Under the menu-vs-meal rule, this is an announcement of the report’s publication, not the report itself.
2026-05-08 English
Rapports financiers et d'audit annuels / Modalités de mise à disposition du rapport financier annuel
Annual Report FY 2025
2026-05-08 French
Rapports financiers et d'audit annuels / Rapport financier annuel
Annual Report FY 2025
2026-05-07 French
Inside Information / Operations of the issuer (acquisitions, sales...)
Report Publication Announcement Classification · 95% confidence The document is a short announcement (under 5,000 characters) regarding a major shareholder (ABL) selling a block of shares in ABL Diagnostics. It explicitly directs the reader to the AMF's BDIF database for the actual regulatory filing details. Since it serves as an announcement of a transaction and points to an external regulatory filing rather than being the primary disclosure document itself, it fits the criteria for a Report Publication Announcement (RPA) or a general regulatory announcement. Given the specific nature of the share block sale notification, RPA is the most accurate classification.
2026-03-17 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.